此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Minipooled-IVIG in Primary Immunodeficiency Disease

2020年5月10日 更新者:Alshaimaa Mokhtar Selim mohamed、Assiut University

Study of Safety and Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Primary Immunodeficiency Patients

  1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)
  2. Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :

    • Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate)
    • Prevention of severe bacterial infection
    • Improvement of general health(weight gain and mentality)
    • Integration in to social live
  3. Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).

研究概览

详细说明

Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for which over 150 forms of PID have been molecularly characterized .

A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons.

A part from local registration in some centres there is no national registry of PID in Egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown .

An increasing number of PID are recognized, and effective treatments are possible. Early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients .

Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing countries .IgG shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. A simple and practical method for producing IgG from normal plasma collected in developing countries is needed to provide better, faster access to IgG for patients .

Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding disorders.

研究类型

介入性

注册 (实际的)

15

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Assiut、埃及
        • Faculty of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 18年 (孩子、成人)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age group: children patients under 18 years.
  • The study will include patient diagnosed as primary immunodeficiency disease (PID) in Assiut university hospital on standard IVIG therapy.

Exclusion Criteria:

  • Patient has SCID.
  • Patient with history of severe IVIG side effect.
  • Patient with severe immunodeficiency and has severe disseminated infection.
  • Patient with renal impairment
  • Patient with hepatic cell failure
  • Patient with endocrinal abnormalities
  • patient with secondary immunodeficiency diseases

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:minipooled- Intravenous immunoglobulin(MP-IVIG)
• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy of MP-IVIG assessed by the incidence of acute Serious Bacterial infections(SBIs)
大体时间:1 year
The rate of Acute SBIs for each participant per 1 year will be assessed by questionnaire (Serious Bacterial Infections) include sign and symptoms of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess.
1 year
Safty of MP-IVIG assessed by percentage of adverse Events
大体时间:72 hour after adminstration of MP-IVIG and betwen infusions period
Overall percentage of adverse events as hemolysis and anaphylaxis headache and other complains that occur during 72 hours of following an infusion of MP-IVIG will be assessed by1) vital sign(pulse,blood pressure,Respiratory rate and temprature 2)Hemolysis by hemoglobin level,LDH,billirubin level.2)lbetwen infusions by home diaries.
72 hour after adminstration of MP-IVIG and betwen infusions period
Study the pharmacokinetics- MP-IVIG trough levels
大体时间:predose sample

MP-IVIG trough level concentration values of serum total IgG pre the MP-IVIG infusion

(if applicable).

predose sample
Study the pharmacokinetics MP-IVIG plasma concentration -time curve
大体时间:(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Blood samples for analysis of pharmacokinetics MP-IVIG plasma concentration -time curve were obtained and analysed
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Study the pharmacokinetics MP-IVIG half-life
大体时间:(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Study the pharmacokinetics MP-IVIG area under the curve
大体时间:(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Study the pharmacokinetics MP-IVIG Cmax
大体时间:(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Blood samples for analysis of pharmacokinetics MP-IVIG Cmax were obtained and analysed
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Study the pharmacokinetics of MP-IVIG-Tmax.
大体时间:(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Blood samples for analysis of pharmacokinetics MP-IVIG Tmax were obtained and analysed
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Study the pharmacokinetics of MP-IVIG elimination rate constant(s).
大体时间:(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Blood samples for analysis of pharmacokinetics MP-IVIG elimination rate constant(s) were obtained and analysed
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

次要结果测量

结果测量
措施说明
大体时间
Compare efficacy of MP-IVIG vs standard IVIG by compare incidence of SBIs of both
大体时间:1 year
• Compare the efficacy of MP-IVIG to standard IVIG in children with Primary immunodeficiency disease (PID).
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Maha A Mohammed, professor、Assiut University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年1月1日

初级完成 (实际的)

2020年5月1日

研究完成 (实际的)

2020年5月1日

研究注册日期

首次提交

2019年3月26日

首先提交符合 QC 标准的

2019年3月28日

首次发布 (实际的)

2019年4月1日

研究记录更新

最后更新发布 (实际的)

2020年5月12日

上次提交的符合 QC 标准的更新

2020年5月10日

最后验证

2020年5月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

minipooled- Intravenous immunoglobulin(MP-IVIG)的临床试验

3
订阅